Generic Name: insulin glulisine
Applies to insulin glulisine: subcutaneous solution
In addition to its needed effects, some unwanted effects may be caused by insulin glulisine (the active ingredient contained in Apidra). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking insulin glulisine:
Some of the side effects that can occur with insulin glulisine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to insulin glulisine: subcutaneous solution
The most common adverse reactions reported include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.[Ref]
Common (1% to 10%): Hypoglycemia, hypoglycemic seizureFrequency not reported: Weight gain[Ref]
In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine (the active ingredient contained in Apidra) compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins.  Permanent discontinuation occurred in 1 patient receiving insulin glulisine.[Ref]
Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus Frequency not reported: Anaphylaxis[Ref]
Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine (the active ingredient contained in Apidra) compared with insulin aspart.[Ref]
Common (1% to 10%): Infusion site reactions Very rare (less than 0.01%): Catheter occlusions[Ref]
Common (1% to 10%): Peripheral edema, hypertension[Ref]
Common (1% to 10%): Diarrhea, pharyngitis, vomiting, nausea[Ref]
Rare (less than 0.1%): Lipodystrophy[Ref]
Common (1% to 10%): Influenza[Ref]
Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis[Ref]
Common (1% to 10%): Arthralgia, back pain[Ref]
Common (1% to 10%): Headache[Ref]
Common (1% to 10%): Urinary tract infection[Ref]
1. Cerner Multum,  Inc. "Australian Product Information." O 0
2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
3. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ. 
Not all side effects for Apidra may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Anxiety
blurred vision
body aches or pain
chills
cold sweats
confusion
convulsions
cool, pale skin
cough
depression
difficulty with breathing
dizziness
ear congestion
fast heartbeat
headache
increased hunger
loss of voice
nasal congestion
nightmares
runny nose
shakiness
slurred speech
sneezing
sore throat
unconsciousness
unusual tiredness or weakness


Pounding in the ears
slow or fast heartbeat


Difficulty with swallowing
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fast, pounding, or irregular heartbeat or pulse
hives
increased sweating
itching
puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
skin rash
tightness in the chest


Difficulty with moving
dry, red, hot, or irritated skin
ear congestion
loss of voice
muscle aches
muscle pain or stiffness
pain in the joints


Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
redistribution or accumulation of body fat

